Boiron SA (EPA:BOI)

Market Cap	498.30M +21.4%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +188.0%
Shares Out	17.36M
PE Ratio	15.27
Forward PE	n/a
Dividend	1.35 (4.70%)
Ex-Dividend Date	Jun 3, 2026

Volume	4,280
Open	27.60
Previous Close	28.70
Day's Range	27.10 - 27.90
52-Week Range	20.85 - 32.25
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,634
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.